SenzaGen has signed a global licensing agreement with Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD™ test to its clients.    GARD™ is a genome-based test, with higher accuracy than other available test methods that gives the customers important safety information whether chemical substances are at risk of causing allergies in humans.   Eurofins BPT is the largest network of harmonized bio/pharmaceutical GMP/GLP product testing laboratories wo...